335 related articles for article (PubMed ID: 31206197)
1. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
Nault JC; Martin Y; Caruso S; Hirsch TZ; Bayard Q; Calderaro J; Charpy C; Copie-Bergman C; Ziol M; Bioulac-Sage P; Couchy G; Blanc JF; Nahon P; Amaddeo G; Ganne-Carrie N; Morcrette G; Chiche L; Duvoux C; Faivre S; Laurent A; Imbeaud S; Rebouissou S; Llovet JM; Seror O; Letouzé E; Zucman-Rossi J
Hepatology; 2020 Jan; 71(1):164-182. PubMed ID: 31206197
[TBL] [Abstract][Full Text] [Related]
2. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.
Ahn SM; Haq F; Park I; Nault JC; Zucman-Rossi J; Yu E
BMC Cancer; 2018 May; 18(1):571. PubMed ID: 29776391
[TBL] [Abstract][Full Text] [Related]
3. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
5. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
6. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
7. Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma.
Chong ML; Knight J; Peng G; Ji W; Chai H; Lu Y; Wu S; Li P; Hu Q
Cancer Genet; 2023 Aug; 276-277():30-35. PubMed ID: 37418972
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
9. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
10. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
[TBL] [Abstract][Full Text] [Related]
11. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
[TBL] [Abstract][Full Text] [Related]
12. β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.
Lu LC; Shao YY; Lee YH; Hsieh MS; Hsiao CH; Lin HH; Kao HF; Ma YY; Yen FC; Cheng AL; Hsu CH
Oncology; 2014; 87(3):159-66. PubMed ID: 25012536
[TBL] [Abstract][Full Text] [Related]
13. Integrated genomic analyses of hepatocellular carcinoma.
Chang YS; Tu SJ; Chen HD; Hsu MH; Chen YC; Chao DS; Chung CC; Chou YP; Chang CM; Lee YT; Yen JC; Jeng LB; Chang JG
Hepatol Int; 2023 Feb; 17(1):97-111. PubMed ID: 36472800
[TBL] [Abstract][Full Text] [Related]
14. A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.
Xu QG; Yuan SX; Tao QF; Yu J; Cai J; Yang Y; Guo XG; Lin KY; Ma JZ; Dai DS; Wang ZG; Gu FM; Zhao LH; Li LQ; Liu JF; Sun SH; Zang YJ; Liu H; Yang F; Zhou WP
J Hepatol; 2019 May; 70(5):904-917. PubMed ID: 30654066
[TBL] [Abstract][Full Text] [Related]
15. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
17. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
19. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
[TBL] [Abstract][Full Text] [Related]
20. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]